Analysis of the tumor biological factor regulating the antibody-delivery

胰腺癌作为一种难治性实体肿瘤，肿瘤间质屏障会干扰抗体的传递。为了提高抗体药物偶联物（antibody drug conjugate， ADC）对此类肿瘤的递送效果并使其治疗效果最大化，确定最合适的药物设计非常重要，例如抗基质抗体与连接物联合用于细胞外药物释放。另一方面，细胞靶向ADC在没有抗体递送干扰的情况下，对恶性淋巴瘤这种基质差的肿瘤有效。在这种类型的ADC中，应选择具有高细胞内化效率的抗体。

In pancreatic cancer as a refractory solid tumor, tumor stromal barrier interferes with antibody-delivery. To improve the delivery and maximize the therapeutic effect of antibody drug conjugate (ADC) against such tumors, it is important to determine the most appropriate drug design e.g. combination of the anti-stroma antibody and the linker for the drug-release outside the cells. On the other hand, cell-targeting ADC is effective against malignant lymphoma as a stroma-poor tumor without the interference of antibody-delivery. In this type of ADC, an antibody having a high cell-internalization efficacy should be selected.